We are live on ! Find out more
SCNI

Scinai Immunotherapeutics
SCNI

12 hedge funds and large institutions have $11.5M invested in Scinai Immunotherapeutics in 2020 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

270% more capital invested

Capital invested by funds: $3.12M → $11.5M (+$8.4M)

100% more funds holding

Funds holding: 6 → 12 (+6)

0.55% more ownership

Funds ownership: 2.19% → 2.74% (+0.55%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

Holders
12
Holders Change
+6
Holders Change %
+100%
% of All Funds
0.25%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
6
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
JSMC
Jess S. Morgan & Co
California
+$1.13M
2
Renaissance Technologies
Renaissance Technologies
New York
+$531K
3
BHB
Bank Hapoalim BM
Israel
+$145K
4
Morgan Stanley
Morgan Stanley
New York
+$64.4K
5
UBS Group
UBS Group
Switzerland
+$32.2K

Top Sellers

Rank Fund Capital Flow
1
II
Ibex Investors
Colorado
-$467K
2
JP Morgan Chase
JP Morgan Chase
New York
-$1K

SCNI Hedge Fund Activity: Q2 2020 in Review

12 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Scinai Immunotherapeutics (SCNI) for Q2 2020, worth a combined $11.5M — up 270% from $3.12M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new SCNI positions and 0 closed out — a net gain of 6 holders — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Jess S. Morgan & Co, opening a new position worth an estimated $1.13M. The largest seller was Ibex Investors, cutting an estimated $467K.

  • 12 institutional investors held Scinai Immunotherapeutics (SCNI) as of Q2 2020, up from 6 in Q1 2020.
  • Funds reported $11.5M of Scinai Immunotherapeutics stock for Q2 2020, up 270% quarter-over-quarter.
  • 6 funds opened new Scinai Immunotherapeutics positions in Q2 2020 and 0 closed out, a net change of +6 holders.
  • The largest Scinai Immunotherapeutics buyer in Q2 2020 was Jess S. Morgan & Co, an estimated $1.13M added.
  • The largest Scinai Immunotherapeutics seller in Q2 2020 was Ibex Investors, an estimated $467K sold.

Based on aggregated 13F filings for Q2 2020.